Kezar Life Sciences Q2 EPS $(0.34) Down From $(0.25) YoY
Portfolio Pulse from Benzinga Newsdesk
Kezar Life Sciences reported Q2 losses of $(0.34) per share, a 36% increase in losses from $(0.25) per share during the same period last year.
August 10, 2023 | 8:38 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Kezar Life Sciences reported a 36% increase in losses YoY, which could negatively impact investor sentiment.
Kezar Life Sciences reported a larger loss in Q2 compared to the same period last year. This indicates a worsening financial situation, which could lead to a decrease in the company's stock price as investors may see this as a negative sign.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100